The East Liberty company Behaivior, which uses artificial intelligence to support addiction recovery, was supposed to have a National Institutes of Health grant application for supplemental funding reviewed this month. It was supposed to have a meeting finalizing the hiring of a new employee through a diversity supplement. And it was supposed to receive an NIH grant Feb. 1 to fund its next budgetary period.
All are now in question because of new policies at the National Institutes of Health, which instituted an external communications ban, postponed grant review meetings and canceled travel last week under a directive from the Trump administration.
“We just don’t know what’s happening,” said Behaivior founder and CEO Ellie Gordon. “We could never have anticipated anything like this.”
NIH funding in Pa.
NIH funding has a huge impact on the Pittsburgh region, which receives hundreds of millions in grant money to support research efforts across multiple universities, foundations and biomedical companies. The University of Pittsburgh receives the lion’s share of the region’s NIH funding, with $661 million in fiscal year 2024. Carnegie Mellon University’s total for the same period was $37 million, and Duquesne University’s was $1.6 million.
Across Pennsylvania, NIH awarded $2.2 billion in grant funding in 2023, supporting 21,787 jobs and $5.2 billion in economic activity, according to the nonprofit United for Medical Research.
Pennsylvania higher education institutions made up two of the top 10 medical schools that received the most NIH funding in the country in 2023, placing a spotlight on the commonwealth as a target for the possible crippling effects of frozen funding.
Read More
The University of Pennsylvania School of Medicine received $580 million from NIH in 2023, making it the third-highest funded medical school in the country, while Pitt’s School of Medicine received $548 million, coming in eighth, according to a report from the Blue Ridge Institute for Medical Research, which has reported top NIH recipients since 2006 using data from NIH’s grant reporting database.
What happened with the NIH funding?
In addition to the NIH restrictions announced last week, an executive order Monday night seemed to freeze grants from NIH and other federal agencies, though that order was halted by a federal judge Tuesday afternoon.
The uncertainty has left researchers scrambling, wondering about the fate of yearslong projects and millions of dollars they’ve been promised.

In an internal email sent to Pitt employees and obtained by the Post-Gazette, the university said it recognized there were many questions and concerns and had established a process to track and review policy directives and executive orders.
“In partnership with University leadership, our Government Relations and Advocacy team remains actively engaged in legislative, regulatory and policy discussions that impact Pitt’s research portfolio, operations and community,” said the email, signed by provost and senior vice chancellor Joseph McCarthy, senior vice chancellor for research Rob Rutenbar and senior vice chancellor for the health sciences Anantha Shekhar.
“While we know there are questions about these changes, along with a strong desire for information about potential impacts, we want to make sure we are thoroughly reviewing the changes before sharing specifics, particularly as some orders work their way through judicial review.” The email also recognized the challenge of “this level of uncertainty.”
What’s at stake?
Craig Kaplan, a professor in Pitt’s department of biological sciences, has a five-year grant from the NIH. Even just a pause in grant review can impact the ability of research groups to conduct research, he said, noting that the process to receive grant funding is quite lengthy and, if one part of the process is disrupted, it’s not a simple matter of a slight delay.
Delays can lead to a backlog of proposals, he said, or, even worse, projects found to have merit could fall apart because of the long delay.
“This could set us back decades, and that’s not hyperbole,” Mr. Kaplan said.
Ms. Gordon, at Behaivior, is trying to figure out how to move forward even in the short term, given the disruptions at NIH. A grant review meeting scheduled for this month was postponed or canceled; it would have provided additional funding for staff and supplies for a program for veterans experiencing opioid use disorder.
“We’re working to help prevent overdoses and support people with chronic mental health issues,” she said. “It’s not a political thing.”
The importance of funding from the NIH for research cannot be overstated, said Daniel Kaplan, a professor of dermatology and immunology at Pitt.
“I would say that all of the research that we do is dependent on funds from the NIH, and our goal is to improve human health through understanding mechanisms of disease and finding therapies,” he said. “And so without the funding from the NIH, that is not possible anymore.”
The NIH is an umbrella organization that oversees multiple organizations, including the National Cancer Institute, National Institute on Aging and National Institute on Drug Abuse. Federal dollars from NIH, when awarded to researchers at universities such as Pitt and CMU, help researchers acquire necessary supplies for their experiments and pay their graduate students and research assistants. These grants also fund clinical trials and studies exploring Alzheimer’s research, cancer and biological studies that aim to identify biomarkers for certain diseases, such as dementia.
Ann D. Cohen, an associate professor of psychiatry at Pitt and co-director of the Alzheimer’s Disease Research Center, has received more than $5 million from the National Institute on Aging to study how Alzheimer’s disease and brain function are impacted by health disparities, such as high blood pressure or low socioeconomic status.
More than 200 Pittsburghers have participated in neuroimaging since their study began in 2022, she said. And their focus on diversity in clinical trials has led to a better understanding of the ways Alzheimer’s impacts Pittsburghers.
“Pittsburgh is well-known internationally as one of the shining examples of development of Alzheimer’s disease research and is considered one of the premier locations in the world to do this kind of work,” Ms. Cohen said. “We could potentially be setting back Alzheimer’s research pretty far if we were to lose funding.”
Ms. Cohen employs a team of 20 to 25 research assistants and graduate students that run PET scans for Pittsburgh participants in their studies and programmers that analyze the data.
All of their salaries — including Ms. Cohen’s — are in jeopardy without that grant funding.
Like many other researchers, Ms. Cohen said she was caught off guard by the announcement of the funding freeze, but her goal is to encourage her team to keep a level head and continue to work to uncover answers about Alzheimer’s, which affects hundreds of thousands of Pennsylvanians over 65.
“The uncertainty is uncomfortable, but the theme has been we keep on keeping on until someone tells us we can’t anymore,” she said.



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.